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Volume 53, Number 17S Abstracts 103Smost common in CAS than in CEA patients (30.7% vs
26.6%, p0.042). Diabetic patients were younger
(p0.005) and more frequently had hypertension
(p0.015) or coronary disease (p0.019). Perioperative
stroke/death rate was 2.3% (36/1568) in non-diabetic vs
2.7% (17/629) in diabetic patients (p0.54); 3.4% in
diabetic CEA group and 2.1% in diabetic CAS group. At
multivariate analyses diabetes was found predictor of peri-
operative stroke/death only in CEA group (OR 3.04;
95%CI 1.107-8.362; p0.031) but not in CAS group
(p0.45) or in overall patients (p0.38). Six-year survival
was 78.4% in diabetic and 82.5% in non-diabetic (p0.15).
The 6-year risk of late stroke was similar (5.0%) in diabetic
and non diabetic patients. Six-year restenosis estimates
were 5% in diabetic and 8% in non-diabetic patients
(p0.1). Survival, late stroke and restenosis rates between
diabetic and non-diabetic were similar in CAS and CEA
groups.
Conclusions: Diabetic patients are not at greater risk
of perioperative morbidity, mortality and late stroke after
CAS.
Author Disclosures: P. Cao: Nothing to disclose; E.
Cieri: Nothing to disclose; P. De Rango: Nothing to
disclose; G. Isernia: Nothing to disclose; G. Parlani:
Nothing to disclose; G. Simonte: Nothing to disclose; F.
Verzini: Nothing to disclose.
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SS32.
Implementation and Early Results of a Hospital Wide
Program to Reduce the Incidence of Venous Throm-
boembolic Events
Nicholas Morrissey, Benjamin Bradley, Robert Green, Si-
kander Khan, Hope Copperstone, Lisa Mainieri, James
McKinsey. Columbia University College of Physicians and
Surgeons Weill/Medical College of Cornell University,
The New York Presbyterian Hospital, New York, NY
Objectives: Venous thromboembolic disease (VTE) is
a major cause of morbidity and mortality in hospitalized
patients. Despite evidence confirming the benefit of pro-
phylaxis, many patients do not receive prevention and
develop VTE.We implemented and studied a hospital wide
program to assure all patients have VTE risk and prevention
addressed.
Methods: Beginning June 2010, all patients admitted
to a 2,300 bed academic medical center had VTE risk
addressed in their electronic admission orders. Risk assess-
ment and prophylaxis were monitored using Microsoft
AMALGA software and hospital electronic health record
(ECLIPSYS). VTE rates were monitored through chart
review by certified coders. Rates were calculated as VTE per
1000 patient discharges and rates were compared with
chi-square. AMALGA software allowed real-time assess-
ment of all patients risk scores and prophylaxis regimens. Ghe number of discharges from the institution is approxi-
ately 62,000 per year.
Results: Data are shown in table 1. Compared to the
rst half of 2010 VTE decreased significantly after im-
lementation of the program. Compliance with prophy-
axis also doubled after implementation. 32% of patients
eemed low-risk by admitting physician were actually
igh risk. Of these, 65% were already on appropriate
rophylaxis. In the remaining 35%, responsible physi-
ians were contacted and prophylaxis implemented un-
ess contraindicated.
Conclusions: A hospital-wide VTE prevention pro-
ram that evaluates all admitted patients is feasible even in
arge medical centers. Preliminary data suggest that there is
significant decrease in VTE events and significant im-
rovement in prophylaxis rates. The AMALGA software
llows real-time monitoring of risk and prophylaxis result-
ng in the ability to correct errors and provide appropriate
rophylaxis when indicated.
Innappropriate
prophylaxis
Rate of VTE per
1000 discharges
re implementation 46% 5.75
ost implementation 22% 4.22
p.011 p .003
uthor Disclosures: B. Bradley: Nothing to disclose; H.
opperstone: Nothing to disclose; R. Green: Nothing to
isclose; S. Khan: Nothing to disclose; L. Mainieri: Noth-
ng to disclose; J. McKinsey: Nothing to disclose; N.
orrissey: Nothing to disclose.
S33.
mpact of Graduated Compressive Stockings on the
Revention of P-Thrombotic syndrome: Results of a
andomized Trial
rjun Jayaraj, Cynthia Natiello, Stephen Nicholls, Mark
eissner. Vascular Surgery, University of Washington, Se-
ttle, WA
Objectives: Post-thrombotic syndrome (PTS) is a
ommon chronic complication of acute deep venous
hrombosis (DVT) in the lower extremity with as many as
wo-thirds of patients developing symptoms of pain,
dema, hyperpigmentation or ulceration. The role of grad-
ated compressive stockings (30-40mmHg knee length) in
he prevention of PTS has been studied with the opinion
eing divided on the beneficial effects. We aim to answer
his question with a randomized controlled study that used
ultiple scoring instruments to assess post thrombotic
yndrome.
Methods: 69 consecutive patients with an acute
VT diagnosed by duplex ultrasonography were ran-
omized to treatment with graduated compressive
tockings (GCS) or no stockings to assess the impact of
CS on the prevention of PTS. Venous Clinical Severity
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June Supplement 2011104S AbstractsScore (VCSS) and PTS scoring put forth by Villalta et al
(PTSV), commonly used scoring systems, were used to
appraise PTS at 3, 6, 12, 18 and 24 months following
diagnosis of DVT. Cumulative incidence (CI) served as
the primary outcome measure.
Results:Asmeasured by VCSS, the GCS (study) group
had a cumulative incidence of PTS that was twice that of the
control group. When PTSV was used as the instrument of
measurement, a significant difference in cumulative inci-
dence of PTS in the GCS and control groups was not
found. The break up of incidence at various time intervals is
depicted in table 1.
Conclusions: Use of knee length graduated compres-
sive stockings does not appear to prevent development of
post thrombotic syndrome. When PTS is assessed by the
VCSS instrument the use of stockings seem to contribute to
the incidence of the syndrome.
Table I.
VCSS (Incidence of PTS) PTSV (Incidence of PTS)
Month GCS Group Control Group GCS Group Control Group
3 58% 36% 50% 72%
6 56% 17% 63% 60%
12 59% 15% 59% 46%
18 73% 33% 59% 52%
24 68% 8% 42% 54%
Author Disclosures: A. Jayaraj: Nothing to disclose; M.
Meissner: Jobst - partial funding for study,Research
Grants; C. Natiello: Nothing to disclose; S. Nicholls:
Nothing to disclose.
VS7.
Video Presentation
Resection of Vena Cava for Invasion by Renal Cell
Carcinoma
R Clement Darling, Benjamin B. Chang, Sean P. Roddy,
Manish Mehta, Philip S. Paty, Kathleen J. Ozsvath, Paul B.
Kreienberg, Yaron Sternbach, John B. Taggert, Dhiraj M.
Shah. Vascular Surgery, Albany Medical Center/Albany
Medical College, Albany, NY
Background: Up to 10% of patients with renal cell
carcinoma will have extension into the inferior vena cava. In
those cases, a vascular surgeon is usually asked to assist the
urologist in resection of the vena cava and removal of the
intra caval thrombus.
Technical Description: This video will outline the
operative approach for isolation of the suprahepatic cava
including the hepatic veins, the infrahepatic and infrarenal
vena cava, and the steps involved with removal of the
thrombus bymilking it back through the cava and resection
of the vena cava with non stenotic reconstruction. We have
performed 69 reconstructions with no perioperative
deaths; 80% of these patients required suprahepatic control
and 10% required median stenotomy for extension of the
thrombus into the atrium. The operative technique will be bllustrated and should be valuable for all surgeons who
articipate in this operation.
uthor Disclosures: B. B. Chang: Nothing to disclose;
. Darling: Nothing to disclose; P. B. Kreienberg: Noth-
ng to disclose; M. Mehta: Nothing to disclose; K. J.
zsvath: Nothing to disclose; P. S. Paty: Nothing to
isclose; S. P. Roddy: Nothing to disclose; D. M. Shah:
othing to disclose; Y. Sternbach: Nothing to disclose;
. B. Taggert: Nothing to disclose.
S34.
linical Research Review
nticoagulation for Calf Deep Venous Thrombosis: A
ystematic Review and Meta-Analysis
andall R. De Martino1, Jessica B. Wallaert2, Ana P.
ossi3, Alicia J. Zbehlik4, Daniel B. Walsh1. 1Section of
ascular Surgery, Dartmouth-Hitchcock Medical Center,
ebanon, NH; 2Department of Surgery, Dartmouth-
itchcock Medical Center, Lebanon, NH; 3The Dart-
outh Institute for Health Policy and Clinical Practice,
ebanon, NH; 4Department of Medicine, Dartmouth-
itchcock Medical Center, Lebanon, NH
Objectives: Review evidence for anticoagulation treat-
ent of calf deep venous thrombosis (CDVT).
Methods: Medline, Cochrane Library, meeting ab-
tracts, and expert opinion were reviewed. Criteria for
tudies selected were: (1) Adults with CDVT by ultrasound
r venogram, (2) comparisons of patients treated with
nticoagulation (vitamin K antagonist or heparin) for 30
ays to controls (not anticoagulated), (3)  one month
ollow-up. Primary outcome was pulmonary embolus (PE).
econdary outcomes were clot propagation, post-throm-
otic syndrome, mortality, and bleeding. Two independent
eviewers extracted data from qualifying articles. Quality
ssessment was performed using standardized scales. Meta-
nalyses were performed by generating pooled odds ratios
ith subgroup and sensitivity analyses.
Results: We reviewed 2,328 studies, including 148 full
ext articles. Eight studies met selection criteria (2 RCTs
nd 6 cohort) providing 126 anticoagulated patients and
78 controls. Most studies were of poor methodological
uality and did not report all outcomes. Rates of PE (OR
.12, 95% CI 0.02-0.77, p0.03) and clot propagation
OR 0.29, 95% CI 0.14-0.62, p0.04, Figure 1) were
ignificantly lower in patients treated with anticoagulation.
ue to heterogeneity, results for bleeding complications
nd mortality could not be pooled, but favored controls or
nticoagulation respectively. No data on post-thrombotic
yndrome were available.
Conclusions: Anticoagulation for CDVT may de-
rease clinically important outcomes such as PE and clot
ropagation. Treatment-related complications have been
oorly documented and studies are of poormethodological
uality. More rigorous studies would improve evidenced
ased treatment for calf vein DVT.
